Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
The clinical advancement of Soquelitinib for atopic dermatitis is progressing, with positive results from Phase 1 cohort 4. Additionally, a Phase 2 trial has been initiated during this quarter. These developments are indicative of the promising trajectory of Soquelitinib for the treatment of atopic dermatitis.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments